Ambee Pharmaceuticals PLC (DSE:AMBEEPHA)
Bangladesh · Delayed Price · Currency is BDT 763.50
-12.00 (-1.55%)
At close: Jun 15, 2026
Ambee Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 157.61 | 230.55 | 219.3 | 198.1 | 180.99 | 98.98 | |
Revenue Growth (YoY) | -32.99% | 5.13% | 10.71% | 9.45% | 82.86% | -65.31% |
Cost of Revenue | 84.67 | 119.16 | 103.14 | 92.53 | 83.62 | 58.27 |
Gross Profit | 72.95 | 111.39 | 116.16 | 105.56 | 97.37 | 40.71 |
Selling, General & Admin | 68.89 | 104 | 103.75 | 92.39 | 82.51 | 47.99 |
Operating Expenses | 68.89 | 104 | 103.75 | 92.39 | 82.51 | 47.99 |
Operating Income | 4.06 | 7.39 | 12.41 | 13.17 | 14.86 | -7.28 |
Interest Expense | -0.03 | -0.09 | -0.58 | -2.49 | -4.62 | -5 |
Interest & Investment Income | 3.6 | - | - | - | - | - |
Other Non Operating Income (Expenses) | 0 | - | 0 | -0 | - | 0 |
EBT Excluding Unusual Items | 7.62 | 7.3 | 11.83 | 10.68 | 10.23 | -12.28 |
Pretax Income | 7.62 | 7.3 | 11.83 | 10.68 | 10.23 | -12.28 |
Income Tax Expense | 2.1 | 1.99 | 2.15 | 1.59 | 2.18 | 0.73 |
Net Income | 5.53 | 5.31 | 9.68 | 9.09 | 8.06 | -13.01 |
Net Income to Common | 5.53 | 5.31 | 9.68 | 9.09 | 8.06 | -13.01 |
Net Income Growth | -45.16% | -45.17% | 6.53% | 12.79% | - | - |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 |
EPS (Basic) | 2.30 | 2.21 | 4.03 | 3.79 | 3.36 | -5.42 |
EPS (Diluted) | 2.30 | 2.21 | 4.03 | 3.79 | 3.36 | -5.42 |
EPS Growth | -45.16% | -45.17% | 6.53% | 12.79% | - | - |
Free Cash Flow | -18.41 | -2.06 | -68.12 | -35.34 | -74.71 | -5.45 |
Free Cash Flow Per Share | -7.67 | -0.86 | -28.39 | -14.72 | -31.13 | -2.27 |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.500 | 1.000 | - |
Dividend Growth | - | - | -33.33% | 50.00% | - | - |
Gross Margin | 46.28% | 48.31% | 52.97% | 53.29% | 53.80% | 41.13% |
Operating Margin | 2.57% | 3.21% | 5.66% | 6.65% | 8.21% | -7.36% |
Profit Margin | 3.51% | 2.30% | 4.42% | 4.59% | 4.45% | -13.14% |
Free Cash Flow Margin | -11.68% | -0.89% | -31.06% | -17.84% | -41.28% | -5.51% |
EBITDA | 8.5 | 12.46 | 18.26 | 20.16 | 19.64 | -1.67 |
EBITDA Margin | 5.39% | 5.40% | 8.32% | 10.18% | 10.85% | -1.69% |
D&A For EBITDA | 4.44 | 5.07 | 5.84 | 6.99 | 4.79 | 5.61 |
EBIT | 4.06 | 7.39 | 12.41 | 13.17 | 14.86 | -7.28 |
EBIT Margin | 2.57% | 3.20% | 5.66% | 6.65% | 8.21% | -7.36% |
Effective Tax Rate | 27.49% | 27.26% | 18.16% | 14.90% | 21.25% | - |
Advertising Expenses | - | 0.82 | 1.12 | 1.43 | 4.58 | 0.93 |